This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignees: Centre National De La Recherche Scientifique, Institut Curie, National Institute of Health and Medical Research. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 5,383 
3 out of 162 
3 out of 1,853 
Years Active: 2022-2025
Title: Leticia Niborski: Innovator in Engineered Immune Cells
Introduction
Leticia Niborski is a prominent inventor based in Paris, France. She has made significant contributions to the field of immunology, particularly in the development of engineered immune cells. With a total of 3 patents, her work focuses on advancing cancer treatment through innovative cellular therapies.
Latest Patents
One of her latest patents involves the creation of immune cells defective for SUV39H1. This invention relates to an engineered immune cell that is specifically designed to inhibit the expression and/or activity of Suv39h1. The engineered immune cell also includes a genetically engineered antigen receptor that binds to a target antigen. This invention is particularly relevant for adoptive therapy, offering new avenues for cancer treatment.
Career Highlights
Leticia has worked with esteemed institutions such as Institut Curie and the Institut National de la Santé et de la Recherche Médicale. Her research has been pivotal in the field of cancer immunotherapy, showcasing her dedication to improving patient outcomes through innovative solutions.
Collaborations
Leticia has collaborated with notable colleagues in her field, including Sebastian Amigorena and Eliane Piaggio. These partnerships have further enriched her research and contributed to her success as an inventor.
Conclusion
Leticia Niborski stands out as a leading innovator in the realm of engineered immune cells. Her patents and collaborations reflect her commitment to advancing cancer treatment through groundbreaking research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile